News & Updates

DERMTECH INTRODUCES PLAPLUS WITH IMPROVED SENSITIVITY FOR EARLY DETECTION OF MELANOMA

04/27/2021

Excerpt from the Press Release: LA JOLLA, Calif.–(BUSINESS WIRE)–Apr. 22, 2021– DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the launch of DermTech PLAplusTM, its next generation test for the enhanced early detection of melanoma. PLAplusdelivers objective and actionable information to guide clinical management decisions…

Read More

Candel Therapeutics Completes Enrollment in Phase 1 Clinical Trial of CAN-2409 in Combination with Opdivo® (nivolumab) for the Treatment of High-Grade Gliomas

04/26/2021

Excerpt from the Press Release: NEEDHAM, Mass.–(BUSINESS WIRE)–Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced it has completed enrollment for its Phase 1 clinical trial in patients with newly diagnosed high-grade glioma to evaluate the safety and efficacy of CAN-2409 in combination with immune checkpoint inhibitor Opdivo® (nivolumab) and…

Read More

Coherus Announces Toripalimab Achieved Primary Endpoints of Progression Free Survival and Overall Survival in Interim Analysis of Phase 3 Clinical Trial in First-Line Esophageal Squamous Cell Carcinoma

04/26/2021

Excerpt from Press Release: REDWOOD CITY, Calif., April 23, 2021 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (Nasdaq: CHRS) has received notice from immuno-oncology partner Junshi Biosciences that the Independent Data Monitoring Committee of the JUPITER-06 clinical trial has determined that toripalimab, an anti-PD-1 monoclonal antibody, in combination with paclitaxel/cisplatin as first-line treatment for patients with advanced…

Read More

Ask Us Anything in Clinical Research – How Using Statisticians Early Plays A Crucial Role In Optimizing Clinical Trials

04/25/2021

On April 21st, we hosted our virtual networking meeting focused on the critical benefits of engaging a Statistician early in your clinical development program. Heather and Christopher along with their guest John Amrhein of McDougall Scientific facilitated a wonderful presentation and discussion around the many different and crucial benefits of engaging a Statistician early to…

Read More

Triage Brain MRIs with AI-Based System

04/25/2021

Excerpt from the Article: MRI has grown in popularity as a tool to image the brain for various diseases or damage, leading to a heavy volume of scans for radiologists to interpret. Using an artificial intelligence (AI)-based system could help automate those interpretations to quickly identify the patients who need the most emergent care. “MRI…

Read More

CHOP-led Research Study Identifies Key Target in Treatment-Resistant Hemophilia A

04/23/2021

Excerpt from the Press Release: PHILADELPHIA, April 15, 2021 /PRNewswire/ — Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting…

Read More

NanoView Biosciences Launches EPIC Study to Investigate Impact of Exosome-Associated Biomarkers for Immuno-Oncology

04/22/2021

Excerpt from the Press Release: BOSTON, April 15, 2021 /PRNewswire/ — NanoView Biosciences Inc. (“NanoView”), a leading biomarker characterization company in the emerging field of extracellular vesicle biology, today announced a collaboration agreement with Beth Israel Deaconess Medical Center (“BIDMC”) to study the involvement of biomarkers carried by exosomes in patients undergoing immune checkpoint inhibitor therapy (“ICIT”) for…

Read More

Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of Patent

04/21/2021

Excerpt from the Press Release: WARRINGTON, Pa., April 19, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has filed a Track One prioritized application with the United States Patent and Trademark Office (USPTO)…

Read More

Translate Bio Announces Publication of Preclinical Results of COVID-19 mRNA Vaccine Candidate MRT5500 in npj Vaccines

04/20/2021

Excerpt from the Press Release: LEXINGTON, Mass., April 19, 2021 (GLOBE NEWSWIRE) — Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the peer-reviewed publication of preclinical results of its COVID-19 vaccine candidate, MRT5500, in the journal npj Vaccines. Preclinical evaluation of MRT5500 demonstrated a favorable immune response profile against SARS-CoV-2 and…

Read More

Arch Therapeutics Provides Corporate Update on Commercialization Efforts and Clinical Results

04/19/2021

Excerpt from the Press Release: FRAMINGHAM, Mass., April 19, 2021 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today provided the following corporate update, in line with its commitment to maintain continuing dialogue with investors and other stakeholders on the progress and…

Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives